Associate Scientist, Metabolism and Proteomics
Agios (agios.com) is a biopharmaceutical company focused on providing medicines for some of the world’s most challenging diseases. We’re committed to applying our scientific leadership in cellular metabolism to transform the lives of patients with genetically defined diseases (GDD), encompassing both rare and more common diseases, and mining the extensive potential in the PK platform. Agios is leading the way in advancing PKR activation for hemolytic anemias, including pyruvate kinase (PK) deficiency, thalassemia and sickle cell disease, and has demonstrated a strong commitment to these patient communities. It continues to foster a productive research engine that yields new insights and potential therapeutic approaches. It’s a company that cares about its work, each other, and the people who are counting on them the most. They’re inspired to think big and welcome the different perspectives and backgrounds needed to deliver extraordinary results. They’re driven to be their best selves, together, so they can reach for the Other Side of Possible.
We are searching for a dynamic Associate Scientist to join our growing Metabolism and Proteomics team. You will be responsible for the design and execution of metabolomics, lipidomics and targeted LC MS experiments to support drug discovery efforts genetically defined diseases. You will have the ability to work cross-functionally as a contribution member to our pre-clinical project teams.
The Metabolism and Proteomics department focuses on quantitatively understanding cellular metabolism, relying on state-of-the-art mass spectrometry methods for proteomics, lipidomics, metabolomics and isotopic labeling studies. Our work includes evaluating disease targets, biological models and characterization of biomarkers to support drug discovery. The successful candidate will have a strong ability to operate and maintain mass spectrometry instrumentation while leveraging their understanding of metabolism to support drug discovery across the portfolio.